1445950-68-4

Upstream product

• 1445950-59-3 C₁₉H₂₈O₈S₂ 
• 546141-40-6 C₁₈H₂₆O₆S 
• 1445950-66-2 C₂₄H₃₃NO₈S 
• 1445950-65-1 C₁₉H₂₅NO₆S 
• 1445950-62-8 C₁₈H₂₅N₃O₅S 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1445950-61-7 C₁₈H₂₇NO₅S 
• 1445950-60-6 C₂₅H₃₂O₈S₂ 

Downstream Products

• 1445950-70-8 C₂₅H₃₇NO₈S 

Relevant academic research and scientific papers

CRYSTALLINE DERIVATIVES OF (S)-1-((2R,3R,4S,5S)-5-ALLYL-3-METHOXY-4-(TOSYLMETHYL)TETRAHYDROFURAN-2-YL)-3-AMINOPROPAN-2-OL

Disclosed are salts of a compound of formula 1, as shown below, where R1, R2, R3, R4, R5, R6 and R7 are as described herein. Also, disclosed is a process for the preparation of the salts of the compounds of formula 1, and intermediates used therein. The salts of the compound of formula 1 can be useful for preparation of halichondrin analogs such as eribulin.

2-((2S,3S,4R,5R)-5-((S)-3-AMINO-2-HYDROXYPROP-1-YL)-4-METHOXY-3-(PHENYLSULFONYLMETHYL)TETRAHYDROFURAN-2-YL)ACETALDEHYDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION

Disclosed is a compound of formula 1, as shown below, where R1, R2, R3, R4, R5, R6 and R7 are as described herein. Also, disclosed is a process for the preparation of compounds of formula 1, and intermediates used therein. The compound of formula 1 can be useful for preparation of halichondrin analogs such as Eribulin.

SYNTHETIC PROCESS FOR PREPARATION OF MACROCYCLIC C1-KETO ANALOGS OF HALICHONDRIN B AND INTERMEDIATES USEFUL THEREIN

Disclosed is a compound of formula (1), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, R7, R7', R8, R9, R10, R11, R12 and R13 are as disclosed herein. Also, disclosed is a process for the preparation of the compound of formula 1, or a pharmaceutically acceptable salt thereof, and5 intermediates used therein. The compound of formula (1) can be used in the preparation of halichondrin analogs, such as Eribulin; and a process for its preparation from the compound of formula (1) is also disclosed.

Early introduction of the amino group to the C27-C35 building block of Eribulin

A new synthetic strategy towards the C27-C35 subunit of Eribulin (1) has been devised to include a protected 1,2-amino alcohol at C34-C35. Early introduction of the C35 amino group in the synthesis of 1 increases the efficiency of the route. This new approach can be accomplished on a multi-gram scale and allows for the successful synthesis of Eribulin.